Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue
The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
· 11/5/2026, 11:07:22 AM· 2 min read
The strong performance the company has delivered in Q2 reflected the strength of the business fundamentals, sustained execution and the resilience of its diversified product portfolio.
Read original story →
